Frontiers in Psychology
March 25, 2022
Wendy T. M. Pots, Farid Chakhssi
31 citations
Psilocybin-assisted psychotherapy, i.e., psilocybin treatment with psychological support, has demonstrated the efficacy of psilocybin to reduce depressive symptoms. However, in clinical trials, the structure of psilocybin-assisted psychotherapy is primarily based on preparation, navigation (support during dosing sessions), and integration. For psychotherapeutic guidance, the application of this...
Psych
March 24, 2022
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch et al.
Strategically timed trauma- and attachment-informed psychotherapy to address underlying emotional wounds, paired with ketamine administered in precision-calibrated doses to ensure high-entropy brain states, may be key to improving the quality and duration of ketamine’s therapeutic efficacy for treatment-resistant depression. This approach optimizes the opportunities for change created by...
Frontiers in Psychiatry
March 23, 2022
Richard Matzopoulos, Robert Morlock, Amy Morlock et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2021.780696.].
Journal of Psychoactive Drugs
March 23, 2022
Mitch Earleywine, Fiona Low, Brianna R. Altman et al.
31 citations
Promising outcomes of Psilocybin-Assisted Therapy (PAT) for depression have generated concerted efforts to replicate, extend, and refine protocols to maximize efficacy. Psychotherapy research reveals that clients benefit most when important components of treatment align with their personal preferences. One open question related to PAT concerns the importance of the psilocybin experience of the...
Current Topics in Behavioral Neurosciences
March 22, 2022
Marina Kojić, Johan Saelens, Bashkim Kadriu et al.
11 citations
The approval of ketamine for treatment-resistant depression has created a model for a novel class of rapid-acting glutamatergic antidepressants. Recent research into other novel rapid-acting antidepressants – most notably serotonergic psychedelics (SPs) – has also proven promising. Presently, the mechanisms of action of these substances are under investigation to improve these novel treatments,...
Depression and Anxiety
March 21, 2022
Holger C Bringmann, Andreas Michalsen, Michael Jeitler et al.
Depression is a global key challenge in mental health care. The implementation of effective, low‐risk and cost‐effective interventions to reduce its disease burden is a necessity. The aim of this study was to investigate the efficacy of the new Meditation‐Based Lifestyle Modification (MBLM) program, a “second‐generation” mindfulness‐based intervention, in depressive outpatients.
Healthcare
March 15, 2022
Alicia Sánchez-pérez, Daniel Mendialdua-Canales, Miriam Hurtado-Pomares et al.
A person affected by Alzheimer's disease (AD) gradually loses the ability to perform activities of daily living and becomes dependent on caregivers, thereby having a negative impact on the caregivers' quality of life. There is evidence that suggests that interventions aimed at caregivers, such as mindfulness, may be effective at reducing this burden and emotional issues, such as depression and...
Journal of Affective Disorders
March 15, 2022
Sona Dimidjian, Julia Kaufman, Natalie Coleman et al.
To address the elevated prevalence of depression, suicide, and suicidal ideation, patients require increased access to effective interventions. Mindfulness-Based Cognitive Therapy has a strong evidence base in relapse prophylaxis and can be delivered digitally through Mindful Mood Balance (MMB). This study was a secondary analysis of the impact of MMB paired with usual depression care (UDC)...
Journal of the Neurological Sciences
March 15, 2022
Darin F Quach, Victoria C De Leon, Charles R Conway
Stemming from the results of the historic STAR-D trial, it is evident that a significant subset of individuals (20-25%) with major depressive disorder (MDD) do not respond to conventional antidepressant medications. As a result, an emphasis has been placed on the development of novel therapeutics for MDD over the last two decades. Recently, substantial research efforts have been focused on the...
Expert Opinion on Drug Safety
March 9, 2022
Anees Bahji, Carlos A. Zarate, Gustavo Vazquez
71 citations
ABSTRACT Background Racemic ketamine and esketamine have demonstrated rapid antidepressant effects. We aimed to review the efficacy and safety of racemic and esketamine for depression. Research design and methods We conducted a PRISMA-guided review for relevant randomized controlled trials of racemic or esketamine for unipolar or bipolar major depression from database inception through 2021. We...
Intelligent Medicine
March 7, 2022
Leah Vines, Diana Sotelo, Allison Johnson et al.
21 citations
Ketamine, a noncompetitive NMDA receptor antagonist, has been exclusively used as an anesthetic in medicine and has led to new insights into the pathophysiology of neuropsychiatric disorders. Clinical studies have shown that low subanesthetic doses of ketamine produce antidepressant effects for individuals with depression. However, its use as a treatment for psychiatric disorders has been...
International Journal of Science and Research (IJSR)
March 5, 2022
C Srilatha, G Deepika
Introduction: Nursing professionals, working in COVID pandemic situation are exposed to various infectious diseases, including those transmitted through the blood or other body fluids and/or airborne infectious agents, the Nursing professionals who are in direct contact with the patients are exposed to highest levels of risk. Nurses are particularly vulnerable to many job-related hazards, and...
Can J Kidney Health Dis
March 4, 2022
Long-term Effects of a Brief Mindfulness Intervention Versus a Health Enhancement Program for Treating Depression and Anxiety in Patients Undergoing Hemodialysis: A Randomized Controlled Trial.
Indian Journal of Psychiatry
March 1, 2022
Many experts believes this undoubtedly that Panic is dangerous than pandemic. Fear, stress, anxiety, depression and obsession out of continuous panic state of mind would be more dangerous than the infection caused by covid19 corona virus during pandemic because if one member of a family is infected by infection than all other members of same family were found to be suffering from the stress and...
Behavioral Science
March 1, 2022
Andrea Poli, A. G. Maremmani, Angelo Gemignani et al.
Mindfulness is a mental state that can be achieved through meditation. So far, studies have shown that practicing mindfulness on a consistent and regular basis can improve attentional functions and emotional well-being. Mindfulness has recently begun to be used in the field of child development. The goal of this study is to assess if a mindfulness program may help primary school students in...
Indian Journal of Psychiatry
March 1, 2022
Deoshree Akhouri, M. Madiha, Owais Ashraf et al.
Background: Irritable Bowel Syndrome (IBS) is a disorder of gastrointestinal system, characterized by abdominal pain, diarrhoea, constipation, or both. IBS-M (diarrhoea and constipation) has reported to cause significant distress to the person and often goes misdiagnosed; leading to different psychological problems such as stress, anxiety, depression, etc. These psychological problems maintain...
Psychology and Psychotherapy Theory Research and Practice
March 2022
Kate Williams, Samantha Hartley, Ian M. Anderson et al.
Mindfulness-based cognitive therapy (MBCT) is an 8-week relapse-prevention intervention designed for people who have experienced multiple episodes of depression and remain vulnerable to relapse. Previous qualitative explorations of the effects of MBCT for people in remission from depression have suggested a number of themes regarding changes arising from participating in MBCT ranging from...
Psychopharmacology
March 1, 2022
Madeline M. Pantoni, Jinah L. Kim, Kaitlin R. Van Alstyne et al.
Abstract Rationale ±3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that shows substantial promise as a psychotherapeutic agent. Still, there is some concern regarding its behavioral toxicity, and its dose-effect relationship is poorly understood. We previously explored the role of dose in the cognitive effects of MDMA in a systematic review of existing literature and found no...
Pain
March 1, 2022
Shana A B Burrowes, Olga Goloubeva, Kristen Stafford et al.
Patients with migraine suffer from high morbidity related to the repeated headache attacks, characteristic of the disorder, poor sleep, and a high prevalence of comorbid psychosocial disorders. Current pharmacological therapies do not address these aspects of migraine, but nonpharmacological treatments such as mindfulness-based stress reduction (MBSR) have been shown to improve both pain and...
Der Nervenarzt
March 1, 2022
Gerhard Gründer, Manuela Brand, Laura Kärtner et al.
Psychedelics, such as psilocybin represent one of the most promising current therapeutic approaches in psychiatry. Psychedelics seem to have not only potent antidepressant effects. Do they also work particularly quickly, i.e. within one day? The available literature on clinical studies of psychedelics in depressive syndromes is presented both from the period up to the prohibition of these...